All Updates

Earlier today, a coalition of patient advocates, legislative champions, public health leaders and concerned cancer survivors, led by the American Cancer Society Cancer Action Network (ACS CAN), came together to applaud the Senate and call on Governor Hochul and Assembly leadership to join the Senate in preserving Medicaid enrollees’ access to biomarker testing.

Dozens of volunteer advocates, including cancer survivors, patients, and caregivers from across Hawai’i united at the state capitol Tuesday for ‘Cancer Action Day’ to urge lawmakers to support several policies to aid in the fight against cancer including a bill that would increase access to colorectal cancer screenings for residents.

JACKSON, Miss. – Cancer advocates are celebrating after Gov. Tate Reeves signed “Jill’s Law” House Bill 565 Monday night, paving the way for increased access to biomarker testing for Mississippians with state-regulated health insurance plans. Biomarker testing is a key tool used by physicians to identify the

ACS CAN Calls on the Governor to Sign Supplemental Appropriations to Fund Life-Saving Program

This week, the American Cancer Society Cancer Action Network submitted comments in a letter opposing several policies in the Patient Protection and Affordable Care Act HHS Notice of Benefit and Payment Parameters proposed rule for plan year 2027.

The General Assembly has approved Senate Bill 161/House Bill 625, a bipartisan proposal to provide Virginians with the option to choose insurance plans with flat-dollar copays for prescription drugs. This would ensure that health plans do not solely rely on coinsurance models where patients are forced to pay a percentage of their medication’s cost. Leading patient advocacy organizations, including the American Cancer Society Cancer Action Network (ACS CAN) and Blood Cancer United (formerly The Leukemia and Lymphoma Society), applaud Virginia lawmakers for passing this critical legislation to ensure patients have affordable and predictable access to life-saving treatment. It now heads to Governor Spanberger’s desk, where over a dozen organizations across the Commonwealth are urging her signature.

The one-house budget proposals revealed a clear divide in the Legislature’s approach to the equitable treatment of disease. The New York State Senate flatly rejected the governor’s proposal to roll back Medicaid coverage criteria for biomarker testing, heeding the calls of cancer survivors, patient advocates and public health organizations, like the American Cancer Society Cancer Action Network (ACS CAN). The Assembly took a more mixed approach accepting parts of the Governor’s proposed language while rejecting others.